Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder
and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on
treatment. Those in which it is unclear will be randomized to continue or withdraw treatment
to determine whether that benefit is related to brivanib